

The reactions of 6-(hydroxymethyl)-2,2-dimethyl-1-azaspiro[4.4]nonanes with methanesulfonyl chloride and PPh₃-CBr₄

Yulia V. Khoroshunova^{*1,2}, Denis A. Morozov¹, Andrey I. Taratayko^{1,2}, Sergey A. Dobrynin¹, Ilya V. Yeltsov², Tatyana V. Rybalova¹, Yulia S. Sotnikova¹, Dmitriy N. Polovyanenko¹, Nargiz B. Asanbaeva^{1,2} and Igor A. Kirilyuk¹

¹ N.N. Vorozhtsov Institute of Organic Chemistry SB RAS, Academician Lavrentiev Ave. 9, Novosibirsk 630090, Russian Federation; horoshunova@nioch.nsc.ru

² Novosibirsk State University, Pirogova Str. 1, Novosibirsk 630090, Russian Federation

* Correspondence: horoshunova@nioch.nsc.ru

Supporting Information

Table of Contents

| | |
|---|-----------|
| 1. IR spectral data | S4 |
| 1.1 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrole (3) (Figure S1) | S4 |
| 1.2 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium bromide (3×HBr) (Figure S2) | S4 |
| 1.3 ((5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-1-(Benzyloxy)-2,2-dimethyl-1-azaspiro[4.4]nonan-6-yl)-methanol (1c) (Figure S3) | S5 |
| 1.4 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (4c) (Figure S4) | S5 |
| 1.5 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,6,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (5c) (Figure S5) | S6 |
| 1.6 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-(Hydroxymethyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-yl benzoate (1d) (Figure S6) | S6 |
| 1.7 3,3-Dimethyl-1,4,5,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(3 <i>H</i>)-yl benzoate (4d) (Figure S7) | S7 |
| 1.8 3,3-Dimethyl-3,4,6,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(1 <i>H</i>)-yl benzoate (5d) (Figure S8) | S7 |
| 1.9 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (13) (Figure S9) | S8 |
| 1.10 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3,4-Trimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium iodide (15) (Figure S10) | S8 |
| 1.11 2,3,3-Trimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (16) (Figure S11) | S9 |
| 2. UV spectral data..... | S9 |
| 2.1 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (13) (Figure S12) | S9 |

| | |
|--|------------|
| 3. ¹H and ¹³C NMR spectral data | S10 |
| 3.1 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrole (3) (Figure S13, S14) | S10 |
| 3.2 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium bromide (3×HBr) (Figure S15, S16)..... | S11 |
| 3.3 ((5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-1-(Benzyloxy)-2,2-dimethyl-1-azaspiro[4.4]nonan-6-yl)-methanol (1c) (Figure S17, S18)..... | S12 |
| 3.4 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (4c) (Figure S19, S20, S21, S22)..... | S13 |
| 3.5 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,6,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (5c) (Figure S23, S24) | S15 |
| 3.6 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-(Hydroxymethyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-yl benzoate (1d) (Figure S25, S26)..... | S16 |
| 3.7 3,3-Dimethyl-1,4,5,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(3 <i>H</i>)-yl benzoate (4d) (Figure S27, S28)..... | S17 |
| 3.8 3,3-Dimethyl-3,4,6,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(1 <i>H</i>)-yl benzoate (5d) (Figure S29, S30) | S18 |
| 3.9 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-ium 2,2,2-trifluoroacetate (14) (Figure S31)..... | S19 |
| 3.10 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3,4-Trimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium iodide (15) (Figure S32, S33) | S19 |
| 3.11 2,3,3-Trimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (16) (Figure S34, S35).... | S20 |
| 4. 2D NMR spectral data | S21 |
| 4.1 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrole (3) (Figure S36, S37, S38) | S21 |
| 4.2 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium bromide (3×HBr) (Figure S39, S40, S41) | S23 |
| 4.3 (2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (4c) (Figure S42, S43, S44)..... | S24 |
| 4.4 (2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,6,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (5c) (Figure S45, S46, S47)..... | S26 |
| 4.5 (3,3-Dimethyl-1,4,5,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(3 <i>H</i>)-yl benzoate (4d) (Figure S48, S49, S50)..... | S27 |
| 4.6 (3,3-Dimethyl-3,4,6,7,8,8a-hexahydrocyclopenta[<i>c</i>]azepin-2(1 <i>H</i>)-yl benzoate (5d) (Figure S51, S52, S53)..... | S29 |
| 4.7 (2,3,3-Trimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (16) (Figure S54, S55, S56) | S30 |
| 5. EPR spectral data | S32 |
| 5.1 (5 <i>R</i> (<i>S</i>),6 <i>R</i> (<i>S</i>))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (13) (Figure S57) | S32 |

| | |
|---|-----|
| 6. Gas chromatography data | S32 |
| 6.1 Gas chromatography data of Hofmann elimination of salt 15 (reaction mass) (Figure S58, Table S1) | S32 |
| 7. X-ray analysis data for compound 3×HBr | S33 |
| 7.1 Experimental details for compound 3×HBr | S33 |
| 7.2 The structure and atom numbering of 3×HBr (Figure S59) | S33 |
| 8. NMR spectrum fine structure analysis | S34 |
| 8.1 (5a <i>S</i> (<i>R</i>),8a <i>R</i> (<i>S</i>))-3,3-Dimethyloctahydro-1 <i>H</i> -cyclopenta[2,3]azeto[1,2- <i>a</i>]pyrrol-4-ium bromide (3×HBr) (Figure S60) | S34 |
| 8.2 Line shape analysis of multiplets for 3×HBr (Figure S61, Table S2) | S35 |
| 9. HPLC analysis | S37 |
| 9.1 HPLC analysis of 2-(benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[<i>c</i>]azepine (4c) and 2-(benzyloxy)-3,3-dimethyl-1,2,3,4,5,6,7,8-octahydrocyclopenta[<i>c</i>]azepine (6c) mixture and pure 4c fraction (Figure S62) | S37 |

1. IR spectral data

1.1 (5a*S*(*R*),8a*R*(*S*))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2-*a*]pyrrole (**3**)




Figure S1. IR spectrum of **3** (neat)

1.2 (5a*S*(*R*),8a*R*(*S*))-3,3-Dimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium bromide (**3**×HBr)




Figure S2. IR spectrum of **3**×HBr (KBr)

1.3 ((5*R*(*S*),6*R*(*S*)-1-(Benzyloxy)-2,2-dimethyl-1-azaspiro[4.4]nonan-6-yl)-methanol (**1c**)




Figure S3. IR spectrum of **1c** (neat)

1.4 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[*c*]azepine (**4c**)




Figure S4. IR spectrum of **4c** (2% solution in CCl₄)




Figure S5. IR spectrum of **5c** (neat)




Figure S6. IR spectrum of **1d** (neat)




Figure S7. IR spectrum of **4d** (neat)




Figure S8. IR spectrum of **5d** (neat)

1.9 (5*R*(*S*),6*R*(*S*))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (**13**)




Figure S9. IR spectrum of **13** (KBr)

1.10 (5*aS*(*R*),8*aR*(*S*))-3,3,4-Trimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium iodide (**15**)




Figure S10. IR spectrum of **15** (KBr)

1.11 2,3,3-Trimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[c]azepine (**16**)




Figure S11. IR spectrum of **16** (neat)

2. UV spectral data

2.1 (5*R*(*S*),6*R*(*S*))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (**13**)





Figure S12. UV spectrum of **13** in EtOH (0.757mg/25ml, L=1cm)

3. ^1H and ^{13}C NMR spectral data

3.1 (5a*S*(*R*),8a*R*(*S*))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2-*a*]pyrrole (**3**)



3.2 (5*aS*(*R*),8*aR*(*S*))-3,3-Dimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium bromide (**3**×**HBr**)




Figure S15. ¹H NMR spectrum of **3**×**HBr** in CD₃OD at 600 MHz




Figure S16. ¹³C NMR spectrum of **3**×**HBr** in CD₃OD at 150 MHz

3.3 ((5*R*(*S*),6*R*(*S*))-1-(Benzyloxy)-2,2-dimethyl-1-azaspiro[4.4]nonan-6-yl)-methanol (**1c**)




Figure S17. ¹H NMR spectrum of **1c** in CDCl₃ at 500 MHz




Figure S18. ¹³C NMR spectrum of **1c** in CDCl₃ at 125 MHz


3.4 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[*c*]azepine (**4c**)

Figure S19. ^1H NMR spectrum of **4c** in CDCl_3 at 400 MHz




Figure S20. ^1H NMR spectrum of **4c** and **6c** mixture in DMSO- d_6 at 500 MHz (T=333 K)






$$T = 333$$


Figure S22. ^{13}C NMR spectrum of **4c** and **6c** mixture in DMSO- d_6 at 125 MHz (T=333 K)

$$T = 333 \text{ K}$$


3.6 (5*R*),6*R*(*S*))-6-(Hydroxymethyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-yl benzoate (**1d**)




Figure S25. ¹H NMR spectrum of **1d** in CDCl₃ at 400 MHz




Figure S26. ¹³C NMR spectrum of **1d** in CDCl₃ at 100 MHz

3.7 3,3-Dimethyl-1,4,5,7,8,8a-hexahydrocyclopenta[*c*]azepin-2(*3H*)-yl benzoate (**4d**)




Figure S27. ¹H NMR spectrum of **4d** in CDCl₃ at 400 MHz




Figure S28. ¹³C NMR spectrum of **4d** in CDCl₃ at 100 MHz

3.8 3,3-Dimethyl-3,4,6,7,8,8a-hexahydrocyclopenta[c]azepin-2(1H)-yl benzoate (**5d**)

T = 333 K




Figure S29. ¹H NMR spectrum of **5d** in DMSO-d₆ at 500 MHz (T=333 K)




Figure S30. ¹³C NMR spectrum of **5d** in DMSO-d₆ at 125 MHz (T=333 K)

3.9 (5*R*(*S*),6*R*(*S*))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-ium 2,2,2-trifluoroacetate (**14**)




Figure S31. ^1H NMR spectrum of **14** in $\text{CDCl}_3\text{-CD}_3\text{OD-CF}_3\text{COOH}$ mixture at 400 MHz

3.10 (5a*S*(*R*),8a*R*(*S*))-3,3,4-Trimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium iodide (**15**)




Figure S32. ^1H NMR spectrum of **15** in $\text{CDCl}_3\text{-CD}_3\text{OD}$ mixture at 300 MHz




Figure S35. ¹³C NMR spectrum of **15** in CDCl₃ at 150 MHz.

4. 2D NMR spectral data.

4.1 (5a*S*),8a*R*(*S*))-3,3-Dimethyloctahydrocyclopenta[2,3]azeto[1,2-*a*]pyrrole (**3**)




Figure S36. ¹H-¹H COSY NMR spectrum of **3** in CDCl₃.




Figure S37. ^1H - ^{13}C HMBC NMR spectrum of **3** in CDCl_3 .




Figure S38. ^1H - ^{13}C HSQC NMR spectrum of **3** in CDCl_3 .

4.2 (5a*S*(*R*),8a*R*(*S*))-3,3-Dimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium bromide (3×HBr)




Figure S39. ^1H - ^1H COSY NMR spectrum of 3×HBr in CD_3OD




Figure S40. ^1H - ^{13}C HMBC NMR spectrum of 3×HBr in CD_3OD




Figure S41. ^1H - ^{13}C HSQC NMR spectrum of **3xHBr** in CD_3OD

4.3 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[*c*]azepine (**4c**)




Figure S42. ^1H - ^1H COSY NMR spectrum of **4c** in CDCl_3




Figure S43. ^1H - ^{13}C HMBC NMR spectrum of **4c** in CDCl_3




Figure S44. ^1H - ^{13}C HSQC NMR spectrum of **4c** in CDCl_3

4.4 2-(Benzyloxy)-3,3-dimethyl-1,2,3,4,6,7,8,8a-octahydrocyclopenta[c]azepine (**5c**)




Figure S45. ^1H - ^1H COSY NMR spectrum of **5c** in DMSO-d_6 ($T=333\text{ K}$)




Figure S46. ^1H - ^{13}C HMBC NMR spectrum of **5c** in DMSO-d_6 ($T=333\text{ K}$)




Figure S47. ^1H - ^{13}C HSQC NMR spectrum of **5c** in DMSO-d_6 ($T=333\text{ K}$)

4.5 3,3-Dimethyl-1,4,5,7,8,8a-hexahydrocyclopenta[*c*]azepin-2(3*H*)-yl benzoate (**4d**)




Figure S48. ^1H - ^1H COSY NMR spectrum of **4d** in CDCl_3




Figure S49. ^1H - ^{13}C HMBC NMR spectrum of **4d** in CDCl_3




Figure S50. ^1H - ^{13}C HSQC NMR spectrum of **4d** in CDCl_3

4.6 3,3-Dimethyl-3,4,6,7,8,8a-hexahydrocyclopenta[*c*]azepin-2(1*H*)-yl benzoate (**5d**)




Figure S51. ^1H - ^1H COSY NMR spectrum of **5d** in DMSO- d_6 (T=333 K)




Figure S52. ^1H - ^{13}C HMBC NMR spectrum of **5d** in DMSO- d_6 (T=333 K)




Figure S53. ^1H - ^{13}C HSQC NMR spectrum of **5d** in $\text{DMSO}-d_6$ ($T=333\text{ K}$)

4.7 2,3,3-Trimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[*c*]azepine (**16**)




Figure S54. ^1H - ^1H COSY NMR spectrum of **16** in CDCl_3




Figure S55. ^1H - ^{13}C HMBC NMR spectrum of **16** in CDCl_3




Figure S56. ^1H - ^{13}C HSQC NMR spectrum of **16** in CDCl_3

5. EPR spectral data

5.1 (5*R*(*S*),6*R*(*S*))-6-((Benzoyloxy)methyl)-2,2-dimethyl-1-azaspiro[4.4]nonan-1-oxyl (**13**)




Figure S57. EPR spectrum of **13** in CH₃OH; field sweep, 100 Gs; modulation amplitude, 0.4 Gs; microwave power, 2.0 mW; time constant, 20.48 ms; spectrum scan time, 21.39 s; number of scans 16.

6. Gas chromatography data

6.1 Gas chromatography data of Hofmann elimination of salt **15** (reaction mass)




Figure S58. Chromatogram of reaction mass from Hofmann elimination of salt **15**.

Table S1. Total Ion Chromatogram of reaction mass from Hofmann elimination of salt **15**.


| Retention Time | Area | Area % | Name |
|----------------|----------|--------|--------|
| 11.816 | 90170 | 0.510 | MM=165 |
| 12.199 | 14640088 | 82.760 | MM=179 |
| 12.516 | 176244 | 0.996 | MM=179 |
| 13.130 | 110428 | 0.624 | MM=195 |
| 13.253 | 90884 | 0.514 | MM=177 |
| 13.837 | 40827 | 0.231 | MM=225 |
| 15.729 | 2541191 | 14.365 | MM=197 |

7. X-ray analysis data for compound **3×HBr**

7.1 Experimental details for compound **3×HBr**

Crystallographic data for salt **3×HBr**: $C_{11}H_{20}N^+Br^-$, M 246.19, orthorhombic, $Pna2_1$, a 13.5147(5), b 8.8425(4), c 10.0361(3) Å, V 1199.35(8) Å³, Z 4, D_{calcd} 1.363 g·cm⁻³, $\mu(\text{Mo-K}\alpha)$ 3.388 mm⁻¹, $F(000)$ 512, (θ 3.07 – 26.42°, completeness 98.5%), T 296(2) K, colorless plate, crystal size (0.80 × 0.50 × 0.18) mm³, transmission 0.0900 – 0.1495, 18018 measured reflections in index range $-16 \leq h \leq 16$, $-11 \leq k \leq 11$, $-12 \leq l \leq 12$, 2394 independent (R_{int} 0.0270), 121 parameters, 11 restraints, R_1 0.0376 (for 1979 observed $I > 2\sigma(I)$), wR_2 0.0962 (all data), GOOF 1.069, largest diff. peak and hole 0.70 and -0.44 e.Å⁻³.

7.2 The structure and atom numbering of **3×HBr**

**Figure S59.** The structure and atom numbering of **3×HBr** (The thermal ellipsoids are drawn at the 30% probability level).

8. NMR spectrum fine structure analysis

8.1 (5a*S*(*R*),8a*R*(*S*))-3,3-Dimethyloctahydro-1*H*-cyclopenta[2,3]azeto[1,2-*a*]pyrrol-4-ium bromide (3×HBr)




Figure S60. NMR spectrum fine structure analysis of 3×HBr

8.2 Line shape analysis of multiplets for 3×HBr

Line shape analysis of multiplets for 3×HBr was performed using the gNMR 5.0 software is shown in **Figure S61**. Parameters of spin system are shown in **Table S2**.

[Budzelaar, P. H. M. "gNMR, version 5.0. 6.0." *Ivorysoft, Nijmegen, Netherlands* (2006).]




Figure S61. Line shape analysis of multiplets for 3×HBr

Table S2. Parameters of spin system for **3×HBr**.

| Nº | Nucleus | n | Shift | Width | J[1] | J[2] | J[3] | J[4] | J[5] | J[6] | J[7] | J[8] | J[9] | J[10] | J[11] | J[12] |
|----|---------|---|-------|-------|--------|------|------|-------|--------|--------|--------|------|------|-------|-------|--------|
| 1 | 1H | 1 | 4,188 | 1,40 | | | | | | | | | | | | |
| 2 | 1H | 1 | 3,505 | 1,71 | -12,25 | | | | | | | | | | | |
| 3 | 1H | 1 | 2,799 | 1,83 | 9,30 | 5,67 | | | | | | | | | | |
| 4 | 1H | 1 | 2,529 | 1,71 | 0,00 | 0,00 | 0,00 | | | | | | | | | |
| 5 | 1H | 1 | 2,362 | 1,30 | 0,00 | 0,00 | 0,00 | 13,26 | | | | | | | | |
| 6 | 1H | 1 | 2,295 | 1,11 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | | | | | | | |
| 7 | 1H | 1 | 2,214 | 1,95 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 6,55 | | | | | | |
| 8 | 1H | 1 | 2,186 | 1,56 | 0,00 | 0,00 | 0,00 | 7,09 | -13,74 | 0,00 | 0,00 | | | | | |
| 9 | 1H | 1 | 2,126 | 1,41 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | -13,44 | 0,00 | 0,00 | | | | |
| 10 | 1H | 1 | 2,108 | 1,55 | 0,00 | 0,00 | 0,00 | 13,35 | 6,41 | 0,00 | 0,00 | 0,00 | 0,00 | | | |
| 11 | 1H | 1 | 1,903 | 1,47 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 13,12 | -14,76 | 0,00 | 6,86 | 0,00 | | |
| 12 | 1H | 1 | 1,890 | 2,15 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 6,58 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| 13 | 1H | 1 | 1,815 | 1,18 | 0,00 | 0,00 | 7,43 | 0,00 | 0,00 | 12,97 | 0,00 | 0,00 | 6,89 | 0,00 | 0,00 | -13,57 |

9. HPLC analysis

9.1 HPLC analysis of 2-(benzyloxy)-3,3-dimethyl-1,2,3,4,5,7,8,8a-octahydrocyclopenta[*c*]azepine (**4c**) and 2-(benzyloxy)-3,3-dimethyl-1,2,3,4,5,6,7,8-octahydrocyclopenta[*c*]azepine (**6c**) mixture and pure **4c** fraction.




Figure S62. The HPLC-UV analysis of **4c** and **6c** mixture (left) and pure **4c** fraction (right); column: Zorbax C8 (250 mm × 4.6 mm, i.d., 5μm); mobile phase: acetonitrile/water (8:2 v/v); flow rate: 1.0 mL/min; wavelength: 260 nm; temperature: 35 °C; sampling volume: 20 μL; insert: UV spectrum of **4c**.